Related Experiment Video
Updated: May 10, 2026
Assessing Specificity of Anticancer Drugs In Vitro
Published on: March 23, 2016
Differential determinants of cancer cell insensitivity to antimitotic drugs discriminated by a one-step cell imaging
Yangzhong Tang1, Tiao Xie, Stefan Florian
11Department of Systems Biology, Harvard Medical School, Boston, MA, USA.
Abstract:
Cancer cells can be drug resistant due to genetic variation at multiple steps in the drug response pathway, including drug efflux pumping, target mutation, and blunted apoptotic response. These are not discriminated by conventional cell survival assays. Here, we report a rapid and convenient high-content cell-imaging assay that measures multiple physiological changes in cells responding to antimitotic small-molecule drugs. Our one-step, no-wash assay uses three dyes to stain living cells and is much more accurate for scoring weakly adherent mitotic and apoptotic cells than conventional antibody-based assays. We profiled responses of 33 cell lines to 8 antimitotic drugs at multiple concentrations and time points using this assay and deposited our data and assay protocols into a public database (http://lincs.hms.harvard.edu/). Our data discriminated between alternative mechanisms that compromise drug sensitivity to paclitaxel and revealed an unexpected bell-shaped dose-response curve for BI2536, a highly selective inhibitor of Polo-like kinases. Our approach can be generalized, is scalable, and should therefore facilitate identification of molecular biomarkers for mechanisms of drug insensitivity in high-throughput screens and other assays.
Insights
A new high-content imaging assay accurately measures cancer cell responses to drugs, identifying mechanisms of drug resistance. This method aids in discovering biomarkers for drug insensitivity in cancer research.
Area of Science:
- Cell biology
- Pharmacology
- Biotechnology
Background:
- Cancer cells develop drug resistance through genetic variations affecting drug response pathways.
- Conventional cell survival assays cannot differentiate these resistance mechanisms.
- Accurate assessment of drug response is crucial for effective cancer therapy.
Purpose of the Study:
- To develop a rapid, high-content cell-imaging assay for measuring physiological changes in cancer cells treated with antimitotic drugs.
- To accurately discriminate between various mechanisms of drug resistance.
- To facilitate the identification of molecular biomarkers for drug insensitivity.
Main Methods:
- A one-step, no-wash high-content cell-imaging assay using three dyes to stain living cells.
- Profiling responses of 33 cell lines to 8 antimitotic drugs at multiple concentrations and time points.
- Data deposited into a public database for accessibility.
Main Results:
- The assay accurately scores weakly adherent mitotic and apoptotic cells, outperforming antibody-based assays.
- Discriminated alternative mechanisms of paclitaxel resistance.
- Revealed an unexpected bell-shaped dose-response curve for BI2536, a Polo-like kinase inhibitor.
Conclusions:
- The developed assay is a scalable and generalizable tool for cancer drug response studies.
- This approach can accelerate the identification of biomarkers for drug resistance.
- Facilitates a deeper understanding of cancer cell drug sensitivity and resistance mechanisms.
